Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib + Temozolomide in Newly Diagnosed Glioblastoma
NCT06780592Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vebreltinib in glioblastoma (GBM), sponsored by Huashan Hospital. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
vebreltinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06780592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780592.